Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | PTGFR | P43088 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5902989 | 0.99 | ACACB (0.40) | ACACBACACAFFAR1FFAR4PTPN1 | |
| SCHEMBL5902654 | 0.93 | ACACB (0.42) | ACACBACACAFFAR1FFAR4PTPN1 | |
| SCHEMBL5902926 | 0.91 | ACACB (0.40) | ACACBACACAFFAR1FFAR4PTPN1 | |
| SCHEMBL5902720 | 0.91 | ACACB (0.42) | ACACBACACAFFAR1FFAR4CPT2 | |
| SCHEMBL12138734 | 0.90 | FFAR1 (0.46) | ACACBACACAFFAR1FFAR4CPT2 | |
| SCHEMBL5902394 | 0.88 | ACACB (0.39) | ACACBACACA | |
| SCHEMBL17764130 | 0.87 | PTPN1 (0.44) | ACACBACACAFFAR1FFAR4PTPN1 | |
| SCHEMBL5902613 | 0.87 | ACACB (0.37) | ACACBACACA | |
| SCHEMBL5902732 | 0.85 | PTPN1 (0.42) | FFAR1FFAR4PTPN1GPR84TBXA2R | |
| SCHEMBL15964202 | 0.85 | ACACB (0.38) | ACACBACACAFFAR1FFAR4CPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402300-B1 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS INC (US) | 2016-05-25 | — | — | EP | claimed |
| EP-2402300-B1 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-7119221-B2 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |